Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-16
1998-06-16
Ulm, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
435 691, 530350, A01N 3718
Patent
active
057670641
ABSTRACT:
Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed. Also disclosed are compositions and methods for regulating an IL-1 mediated immune or inflammatory response in a mammal.
REFERENCES:
patent: 4675285 (1987-06-01), Clark et al.
Symons and Duff, FEBS Letters 272:133; 1990.
Dower et al., Nature (London) 324:263 (1986).
Sims et al., Science 241: 585 (1988).
Sims et al., Proc. Natl. Acad. Sci. USA 86: 8946 (1989).
Matsushima et al., J. Immunol. 136: 4496 (1986).
Horuk et al., J. Biol. Chem. 262:16275 (1987).
Rhyne et al., Clin. Immunol. and Immunopathol. 48: 354 (1988).
Tanaka et al., J. Immunol. 142: 167 (1989.
Bomsztyk et al., J. Biol. Chem. 264: 6052 (1989).
Scapigliati et al., FEBS Letters 243: 394 (1989).
Bensimon et al., J. Immunol. 142:2290 (1989).
Bensimon et al., J. Immunol. 143:1168 (1989).
Bomsztyk et al., Proc. Natl. Acad. Sci. USA 86: 8034 (1989).
Chizzonite et al., Proc. Natl. Acad. Sci. USA 86: 8029 (1989).
Mizuno et al., FEBS Letters 257: 27 (1989).
Savage et al., Cytokine 1: 23 (1989).
Horuk et al., Biochem. J. 260: 657 (1989).
Solari, Cytokine 2: 21 (1990).
Eastgate et al., FEBS Letters 260: 213 (1990).
Benjamin et al., Blood 75: 2017 (1990).
Okayama and Berg, Mol. Cell. Biol. 2:161 (1982).
Okayama and Berg, Mol. Cell. Biol. 3:280 (1983).
Aruffo and Seed, Proc. Natl. Acad. Sci. USA 84:8573 (1987).
Yamasaki et al., Science 241:825 (1988).
Yates et al., Proc. Natl. Acad. Sci. USA 81: 3806, (1984).
Lupton et al., Mol. Cell. Biol. 5: 2533 (1985).
Pfitzner et al., J. Virol. 61: 2902 (1987).
Klemenz et al., Proc. Natl. Acad. Sci. USA 86: 5708 (1989).
Tominaga, FEBS Letters 258: 301 (1989).
Fearon et al., Science 247: 49 (1990).
Gearing et al., EMBO 8:3367 (1989).
Giri et al., J. Biol. Chem. 265:17416-17419 (1990).
Smith et al. Science 238:1704-07 (1987).
Sims et al. Proc. Natl. Acad. Sci. USA 90:6155-6159 (1993).
Colotta et al. Science 261:472-475 (1993).
Leonard et al., Nature 311:676 (1984).
Belyavsky et al., Nucl. Acids Res. 17:2919 (1989).
Treiger et al., J. Immunol. 136:4099 (1986).
Cosman David J.
Dower Steven K.
Lupton Stephen D.
Mosley Bruce A.
Sims John E.
Henry Janis C.
Immunex Corporation
Perkins Patricia Anne
Ulm John
LandOfFree
Soluble type II interleukin-1 receptors and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble type II interleukin-1 receptors and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble type II interleukin-1 receptors and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1725991